πŸ‡ΊπŸ‡Έ FDA
Patent

US 11215617

Treatment of metastatic prostate cancer

granted A61KA61K31/277A61K31/337

Quick answer

US patent 11215617 (Treatment of metastatic prostate cancer) held by The Regents of the University of California expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/277, A61K31/337, A61K31/405, A61K31/4166